Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01528787 · ClinicalTrials.gov registry record · Phase 2
Study of AR-13324 in Patients With Elevated Intraocular Pressure
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT01528787: Completed Phase 2 study, sponsored by Aerie Pharmaceuticals.
NCT01528787 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 85 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01528787, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days. The first dose and last dose will be administered in the clinic. Ocular safety and ocular hypotensive efficacy will be evaluated in the clinic throughout the study.
Primary Outcome
The primary efficacy outcome was the mean IOP across subjects within treatment group at each post-treatment timepoint of Day 8. Instillation of study treatment commenced on Day 2 following measurement of IOP. IOP was measured at 0800, 1000, 1200 and 1600 hours on days 2 and 8. IOP was also measured at 0800 hours on Day 4.
Interventions
- DRUG AR-13324 Ophthalmic Solution 0.02%
- DRUG AR-13324 Ophthalmic Solution 0.04%
- DRUG AR-13324 Ophthalmic Solution 0.01%
- OTHER AR-13324 Ophthalmic Solution Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
What the finished NCT01528787 record still lists
NCT01528787 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 4 interventions - of which AR-13324 Ophthalmic Solution 0.02% is the first listed.
NCT01528787 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01528787 about?
NCT01528787 is a clinical study titled "Study of AR-13324 in Patients With Elevated Intraocular Pressure". In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days. The first dose and last dose will be administered in the clinic. Ocular...
What is the current status of trial NCT01528787?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2012-03. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01528787?
The interventions under investigation include: AR-13324 Ophthalmic Solution 0.02% (DRUG), AR-13324 Ophthalmic Solution 0.04% (DRUG), AR-13324 Ophthalmic Solution 0.01% (DRUG), AR-13324 Ophthalmic Solution Vehicle (OTHER).
Who is sponsoring clinical trial NCT01528787?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01528787's enrollment target sits among peer trials
85 820th of 2000 higher than 1,179 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia